Berthier T
France
Research Article
Interest of Botulinum Toxin for Treatment of Spasticity in Multiple Sclerosis
Author(s): Gallien P, Petrilli S, Autret K, Robineau S, Le Meur C, Berthier T, A Durufle, Houedakor J, Fraudet B and Nicolas BGallien P, Petrilli S, Autret K, Robineau S, Le Meur C, Berthier T, A Durufle, Houedakor J, Fraudet B and Nicolas B
Background: Pyramidal tract lesions are common in multiple sclerosis (MS) patients and cause symptoms of spasticity, weakness and paralysis. OnabotulinumtoxinA treatment for spasticity is well-recognised, but remains to be defined in MS.
Objective: Analysis of practices in the treatment of spasticity in MS in a rehabilitation centre: Treatment of spasticity in MS with onabotulinumtoxinA according to level of disability.
Methods: Retrospective patient data review was conducted on MS patients treated with onabotulinumtoxinA from 2007 to 2010 in our neurologic rehabilitation center, with the aim to assess the modalities of use and effectiveness of onabotulinumtoxinA injections in everyday clinical practice.
Results: 126 patients (mean age: 49.4 ± 11 years), with a mean Expanded Disabi.. Read More»
